PDC and neoplasm: Treatment with PHD2 inhibitor roxadustat in a syngeneic model of lung cancer and melanoma reduces tumor growth by increasing the macrophages’ phagocytic activity and by inducing tumor vessel normalization, through the PHD–HIF axis112 (Fig. 5).